And other biotech news brought to you by The Readout.

NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday issued two final guidances, in which it recommended against making Eisai and Biogen's Leqembi (lecanemab) and Eli ...

Note that some links may require registration or subscription. Three people died and 16 have been hospitalized in a listeria ...

And more pharma news updates from Pharmalittle.

Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

About 5.5 million Americans live with dementia, requiring US$53 billion in annual medical spending on doctor visits, ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

NICE decided that two Alzheimer’s drugs are too expensive for their modest benefits and cannot be recommended for NHS use in ...